Newsroom News At Zentiva, we provide health and wellbeing for all generations Zentiva appeals EU court decision on Urban Wastewater Directive Appeal defends patient access, affordability of medicines and fundamental EU legal principles Newsroom Prague / Brussels, 27 April 2026 – The EU Urban Wastewater Treatment Directive (UWWTD) continues to raise serious concerns. Zentiva and other companies in the off patent medicines sector have therefore filed an appeal before the Court of Justice of the European Union (CJEU), which seeks to set aside an earlier order of inadmissibility and enable substantive judicial review following annulment action brought by the companies in March 2025.Through Council statements and EPSCO* debates, 24 of the 27 EU Member States have raised concerns, expressed doubts, or requested further clarification on the Directive or its impacts. Despite this, the Directive is now being implemented at national level. The Directive in its current form poses a serious risk to the availability, affordability, and accessibility of medicines across Europe - on which millions of people depend every day. The companies therefore request a pause, repair and relaunch of the Directive.Zentiva, a leading European manufacturer of generic medicines, fully supports the objective of further reducing micropollutants in urban wastewater, but strongly rejects the extended producer responsibility (EPR) scheme as a disproportionate and unjustified application of the “polluter pays” principle. Micropollutants originate from a wide range of industrial and consumer sources -not only from the use of human medicines and cosmetics. The EPR scheme would mean that medicine and cosmetics producers have to pay for the removal of micropollutants not caused by them while other producers will not bear any cost. Overall, the EPR scheme violates the “polluter pays” principle and risks undermining patient access to essential medicines, placing a disproportionate burden on the generic medicines sector – the backbone of European healthcare – without delivering meaningful environmental benefits. Etiam malesuada tempus viverra Generic medicines account for around 70% of all medicines dispensed in Europe and nine out of ten medicines on the EU list of critical medicines (IQVIA, 2024). These medicines make a significant contribution to public health. Yet generic manufacturers operate under strict price regulation and very low margins. Unlike other industries, they cannot increase prices to absorb additional costs due to statutory price and reimbursement controls in most Member States.Independent studies in several countries  indicate that the costs of the UWWTD have been significantly underestimated, creating a risk of medicine shortages, higher healthcare costs, and a loss of competitiveness for an entire industry sector.While fully committed to protecting the environment, Zentiva highlights that the UWWTD’s EPR scheme does not incentivise “greener” medicines. Under the current regulatory framework, medicines cannot be reformulated within meaningful timelines or replaced without many years of research, regulatory approval, and patient safety assessments. As a result, the Directive risks increasing costs without delivering corresponding environmental benefits, while creating negative consequences for patients and healthcare systems.The appeal seeks to set aside the General Court’s order of inadmissibility and to enable substantive judicial review following the annulment action brought by Zentiva and other companies in March 2025. Through this annulment action, Zentiva challenges Articles 9 and 10, in conjunction with Annex III of the UWWTD, which establish the extended producer responsibility (EPR) by allocating at least 80% of the costs of the new, so called quaternary wastewater treatment to pharmaceutical and cosmetic producers.Despite being directly and individually affected, Zentiva and other generic companies were denied the opportunity to have the substance of their case heard. Zentiva seeks judicial review of the Directive to ensure compliance with fundamental EU legal principles, while safeguarding continued patient access to affordable medicines.Zentiva remains firmly committed to environmental responsibility. According to EcoVadis 2025, its sustainability program ranks among the top 2% of the pharmaceutical industry.*Employment, social policy, health and consumer affairs council – a meeting of national government ministers.  Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents in over 30 countries, bonded together by a commitment to the people who depend on our products every day. Visit us at www.zentiva.com or on LinkedIn About Zentiva Media contact:  Newsroom

Zentiva appeals EU court decision on Urban Wastewater Directive

2026-04-27-uwwtd

Newsroom News At Zentiva, we provide health and wellbeing for all generations GTCR Completes Acquisition of Zentiva Chicago, IL; Prague, Czech Republic; April 9, 2026 - GTCR, a leading private equity firm, announced today that it has closed the previously announced acquisition of Zentiva (the “Company”), a leading European generics pharmaceutical company, from Advent, a leading global private equity investor. Newsroom Zentiva is focused on the development, manufacturing and supply of generic, branded specialty and over-the-counter medicines and products, serving more than 100 million people across over 40 countries. The Company is supported by established R&amp;D capabilities and a deep commitment to clinical excellence and product quality across its portfolio.GTCR will partner with Zentiva’s management team, led by Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy, to support the Company’s next phase of growth. GTCR has longstanding relationships with both Mr. Saltofte and Mr. Murphy, both seasoned leaders with proven track records at various healthcare businesses, including at Acino and GE HealthCare.GTCR has a long history of investing in healthcare over the past 45 years, including in the pharmaceutical sector. The firm will support Zentiva’s next phase of growth through continued investment in new product development, portfolio breadth, and geographic reach, with a focus on improving patient access to essential medicines and supporting sustainable healthcare systems.   Etiam malesuada tempus viverra “We are excited to partner with Steffen and the Zentiva team to further the Company’s success,” said Sean Cunningham, Managing Director and Head of Healthcare at GTCR. “As policymakers increasingly prioritize expanding access to essential medicines while ensuring long-term sustainability of healthcare systems, Zentiva plays a critical role in delivering high-quality, cost-effective therapies at scale. Combined with its differentiated geographic footprint and low-cost manufacturing capabilities, Zentiva is well positioned to strengthen its competitive advantage and deliver long-term growth and impact.”Tom Allen, Managing Director at Advent, added, “We are immensely proud of the business Zentiva has become during our partnership — a scaled, growing European generics platform, with a strong competitive footprint, a commitment to quality, and a clear mission to expand access to affordable medicines. We would like to thank Steffen and all the talented Zentiva team members who played a part in the company’s transformation.  We look forward to watching Zentiva go from strength to strength in the years ahead.”GTCR was advised by Barclays Bank PLC, acting through its Investment Bank, and BNP Paribas as lead financial advisors, Morgan Stanley &amp; Co. LLC as a financial advisor, and Kirkland &amp; Ellis LLP as legal advisor.Advent was advised by Goldman Sachs and PJT Partners as lead financial advisors and Freshfields as lead legal advisor. Downloads Press release Press release Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business &amp; Consumer Services, Financial Services &amp; Technology, Healthcare and Technology, Media &amp; Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn. About GTCR Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe and beyond. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents, bonded together by a commitment to the people who depend on our products every day.  Visit us at www.zentiva.com  About Zentiva Advent is a leading global private equity investor committed to working in partnership with management teams, entrepreneurs, and founders to help transform businesses. With 16 offices across five continents, we oversee more than USD $100 billion in assets under management* and have made 448 investments across 44 countries.Since our founding in 1984, we have developed specialist market expertise across our five core sectors: business &amp; financial services, consumer, healthcare, industrial, and technology. This approach is bolstered by our deep sub-sector knowledge, which informs every aspect of our investment strategy, from sourcing opportunities to working in partnership with management to execute value creation plans. We bring hands-on operational expertise to enhance and accelerate businesses.As one of the largest privately-owned partnerships, our 655 colleagues leverage the full ecosystem of Advent’s global resources, including our Portfolio Support Group, insights provided by industry expert Operating Partners and Operations Advisors, as well as bespoke tools to support and guide our portfolio companies as they seek to achieve their strategic goals.To learn more, visit our website or connect with us on LinkedIn.*Assets under management (AUM) as of September 30, 2025. AUM includes assets attributable to Advent advisory clients as well as employee and third-party co-investment vehicles. About Advent Media Contacts Newsroom

GTCR Completes Acquisition of Zentiva

2026-04-09-gtcr-completes-acquisition-of-zentiva

GTCR to support Zentiva’s next phase of growth, building on its strong foundation of quality, scale and market leadership

Newsroom News At Zentiva, we provide health and wellbeing for all generations Zentiva publishes 2025 Sustainability Report reinforcing commitment to people, partners and the planet.  Newsroom Prague, March 16, 2026 – Zentiva today publishes its 2025 Sustainability Report, presenting another year of progress in public health impact, environmental stewardship and responsible business practices.In 2025, Zentiva demonstrated once again that business growth and environmental responsibility can go hand in hand, cutting emissions by 10 percent across its own operations (Scope 1 &amp; 2 emissions) while increasing net sales and EBITDA.The Science Based Targets initiative (SBTi) validated Zentiva’s near-term and long-term targets - including a 63% reduction of Scope 1, 2 and 3 emissions by 2034, and net zero by 2050.Key achievements in 2025 include:83% of electricity used across Zentiva operations is now from renewable sources – and a full 100% across EU manufacturing sites.The volume of water recycled and reused between 2021 and 2025 almost doubled.47% of waste diverted from disposal – reused, recycled or otherwise repurposed.130,000+ trees planted to assist reforestation and 3.5 million bees adopted as part of Zentiva projects to support biodiversity and be a ‘responsible corporate citizen’.120+ ‘people and community’ projects delivered in Europe and India.  #WeHelpOthersZentiva received a Gold medal from EcoVadis, positioning the Sustainability program in the top 2% of the pharmaceutical industry. We were also pleased to receive a Transparency Award 2025 from EUPD Group for our sustainability reporting and communication. Etiam malesuada tempus viverra As a leading provider and manufacturer of off patent medicines in Europe, Zentiva plays a critical role in ensuring that people across the continent can access the high quality and affordable medicines they depend on every day. Off patent medicines represent roughly 70% of all dispensed medicines, yet only 19% of pharmaceutical spending, making them essential to the affordability and sustainability of public health systems (IQVIA, 2024).Zentiva continues to invest in its manufacturing footprint and sustainability strategy to ensure patients have consistent access to medicines - today and in the future.The Zentiva 2025 Sustainability Report is available at www.zentiva.com/sustainability. 2025 Sustainability Report Zentiva provides health and wellbeing for all generations, with focus on developing, producing, and delivering high-quality, affordable medicines to more than 100 million people in over 40 countries across Europe. Zentiva has four manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Zentiva employs more than 5,400 unique talents in over 30 countries, bonded together by a commitment to the people who depend on our products every day. Visit us at www.zentiva.com. About Zentiva For further information or queries please contact: Newsroom

Zentiva publishes 2025 Sustainability Report reinforcing commitment to people, partners and the planet.

2026-03-16-sustainability-report-2025

zentiva

daily

Header

Footer

Default

Home

Zentiva

At Zentiva, we provide health and wellbeing for all generations

Find out more

Who we are

Discover our portfolio

Join our team!

News

Zentiva appeals EU court decision on Urban Wastewater Directive

GTCR Completes Acquisition of Zentiva

Zentiva publishes 2025 Sustainability Report reinforcing commitment to people, partners and the planet.

Explore

Stay tuned

Get in touch